Current Report Filing (8-k)
December 29 2016 - 3:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 25, 2016
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
DELAWARE
|
000-51436
|
20-2903526
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
248
Route 25A, No. 2
East
Setauket, New York 11733
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: 631 942 7959
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (See General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01 Entry Into a Material Agreement
The
Company has provided notice to Taipei Medical University (“TMU”) that the Exclusive License Agreement dated as of
December 25, 2015 between the Company and TMU is terminated effective December 25,2016. The notice stated that the termination
was due to the failure of TMU to file with and obtain by December 25,2016 approval from the U.S. Food and Drug Administration
of an investigational new drug application for treatment of Hepatocellular Carcinoma using the Company’s licensed technology.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
December 29, 2016
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
|
|
|
|
|
By:
|
/s/
JOHN S. KOVACH
|
|
|
John
S. Kovach, Chief Executive Officer
|